Breaking News

Akorn Completes VersaPharm Acquisition

August 12, 2014

Expands presence in dermatology market

Akorn, Inc. has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million, expanding its presence in the dermatology market. The transaction is expected to add $90 to $100 million in annual revenues. 
 
"We are excited to announce that we have completed the acquisition of VersaPharm," said Raj Rai, chief executive officer of Akorn. "This highly strategic acquisition further strengthens our niche portfolio and accelerates our long-term growth opportunities."

blog comments powered by Disqus